From the Vault: What unique challenges arise when building a disease model for NASH prevalence and what strategies do leading modelers use to overcome them?
Jörn Schattenberg, Louise Campbell, Stephen Harrison and Roger Green share “SurfingNASH predictions” of the most important events that will take place between the 5th and 6th International NASH Days.
This conversation From the Vault visits the 2022 Liver Conference coverage of pediatric NASH and NAFLD with guest, Naim Alkhouri.
In this episode From the Vault, Jeff Lazarus and Roger Green discuss the ease of creating valuable metrics in a comprehensive care model, while our three practitioners — Stephen Harrison, Jörn Schattenberg and Louise Campbell — dive further into how they believe this model will improve care.
Learn about the amazingly diverse and exciting program for Day Two of the inaugural Innovations in NAFLD Care 2022 Workshop, with sessions on Comprehensive Care pathways, current and future pharmacotherapies, and what a future integrated treatment roadmap might look like.
Earlier this year, the “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) got back together with no other guests to talk about the role that combination NASH drugs and greater population diversity in clinical trials will play to strengthen NASH drug development.
This episode discusses the unique role NASH cirrhosis studies can play in clinical trial design, particularly in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.
In this conversation from September 2021, Anthony Villiotti of NASH kNOWledge joins Louise Campbell and Roger Green to discuss his “biggest story of the summer:” two publications, on demonstrating that NASH prevalence and incidence may be far higher than we believe and another demonstrating how limited public knowledge about NASH is today.
From February of this year, Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to discuss the formation of the new NAIL-NIT consortium, led by Stephen and Mazen. This conversation focuses on the specific challenges inherent in the NAS scores.
From November 2021, the Surfers and guests Manal Abdelmalek and Ian Rowe discuss highlights from the previous week’s AASLD 2021 meeting. This episode focuses on the question of how to “put a big, fat dent” in Fatty Liver disease. One answer: Transition more quickly to NITs.
